×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| ZIM Laboratories Limited | 729.03 | -16.92 | 714.28 | -0.35 | 366.0 | 39.0 |
| SMS Lifesciences India Ltd | 800.52 | 51.58 | 790.43 | 17.06 | 352 | 20.4 |
| LYKA LABS LTD. | 298.43 | 8.14 | 291.76 | 0.22 | 351 | 46.8 |
ZIM Laboratories Limited, with Security Code 541400, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 104.4 | 67.0 | 85.3 | 95.8 | 117.4 | 82.0 | 89.7 | 95.4 | 108.5 | 71.4 |
| Expenses | 89.4 | 62.5 | 76.3 | 84.6 | 102.0 | 74.1 | 81.3 | 83.6 | 93.3 | 67.1 |
| Operating Profit | 15.1 | 4.5 | 9.0 | 11.2 | 15.4 | 7.9 | 8.4 | 11.8 | 15.3 | 4.3 |
| OPM % | 14.41% | 6.77% | 10.51% | 11.66% | 13.14% | 9.61% | 9.35% | 12.33% | 14.06% | 6.07% |
| Other Income | 0.7 | 0.6 | 1.4 | 1.1 | 1.5 | 1.0 | 1.3 | 1.8 | 1.6 | 1.5 |
| Interest | 1.3 | 1.7 | 1.2 | 1.7 | 2.3 | 2.9 | 2.9 | 2.7 | 2.9 | 3.3 |
| Depreciation | 4.6 | 3.7 | 3.7 | 3.6 | 3.9 | 4.9 | 5.0 | 4.8 | 5.2 | 4.8 |
| Profit before tax | 9.9 | -0.2 | 5.5 | 7.0 | 10.8 | 1.1 | 1.9 | 6.0 | 8.7 | -2.3 |
| Tax % | -27.9% | -35.9% | -23.3% | -31.1% | -27% | 30% | 34.3% | -27.9% | -37% | 25.9% |
| Net Profit | 7.1 | -0.1 | 4.2 | 4.8 | 7.9 | 0.8 | 1.2 | 4.3 | 5.4 | -1.7 |
| EPS in Rs | 1.46 | -0.03 | 0.86 | 0.99 | 1.62 | 0.16 | 0.25 | 0.89 | 0 | -0.35 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 101.0 | 105.4 | 67.4 | 85.8 | 96.3 | 117.9 | 81.8 | 92.1 | 96.3 | 108.7 |
| Expenses | 87.9 | 90.0 | 62.6 | 76.5 | 84.8 | 102.2 | 73.8 | 82.6 | 84.8 | 94.1 |
| Operating Profit | 13.1 | 15.5 | 4.8 | 9.3 | 11.5 | 15.6 | 8.0 | 9.5 | 11.6 | 14.6 |
| OPM % | 12.97% | 14.66% | 7.16% | 10.87% | 11.98% | 13.28% | 9.82% | 10.34% | 12% | 13.46% |
| Other Income | 2.4 | 0.7 | 1.1 | 1.4 | 1.1 | 1.5 | 1.0 | 1.3 | 1.8 | 1.7 |
| Interest | 1.6 | 1.3 | 1.7 | 1.2 | 1.7 | 2.3 | 2.9 | 2.9 | 2.7 | 2.9 |
| Depreciation | 3.9 | 4.9 | 4.0 | 4.1 | 3.9 | 3.9 | 4.9 | 5.0 | 4.9 | 5.3 |
| Profit before tax | 10.0 | 9.9 | 0.2 | 5.4 | 7.0 | 11.0 | 1.2 | 3.0 | 5.7 | 8.1 |
| Tax % | -33.9% | -27.2% | 22.2% | -23.8% | -31.8% | -26.5% | -27.2% | -19.6% | 29.9% | -39.5% |
| Net Profit | 6.6 | 7.2 | 0.2 | 4.2 | 4.8 | 8.1 | 0.9 | 2.4 | 4.0 | 4.9 |
| EPS in Rs | 1.35 | 1.48 | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 46% |
| 3 Years: | -3% |
| TTM: | -30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 33% |
| 3 Years: | 7% |
| 1 Year: | -16% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | -6% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 33% |
| 3 Years: | 7% |
| 1 Year: | -16% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|